This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The Washington Post, June 16, 1992.
The Washington Post, March 7, 1991.
January 1994 written communication of positions of the Biotechnology Industry Organization to Mr. Kjeldgaard. The price control mechanisms referred to by the Biotechnology Industry Organization were an advisory committee on the reasonableness of prices for breakthrough drugs and granting authority to HHS to exclude excessively priced drugs from Medicare. The creation of a board thst can revoke patent rights for excessively priced drugs is plainly another indirect control on prices.
Reported in F.M. Schere, Pricing, Profits and Technological Progress in the Pharmaceutical Industry. 7 Journal of Economic Perspectives, 97–115.
Author information
Author notes
Richard H. Kjeldgaard is a partner at the law firm of Howrey and Simon, 1299 Pennsylvania Ave., N.W., Washington, D.C. 20004-2402. David Marsh holds a PhD. from the Institute of Plant Science Research, Cambridge, U.K., and is currently a student at New York University School of Law. The opinions expressed here are those of the authors, and not necessarily those of Howrey and Simon.
Rights and permissions
About this article
Cite this article
Kjeldgaard, R., Marsh, D. Health-Care Reform and Intellectual Property. Nat Biotechnol 12, 639–640 (1994). https://doi.org/10.1038/nbt0694-639
Issue date:
DOI: https://doi.org/10.1038/nbt0694-639
This article is cited by
-
Health-Care Reform and Intellectual Property
Nature Biotechnology (1994)
